High-density lipoprotein and endothelial function in patients with myocardial infarction: Pieces in a puzzle  by Martin, Seth S. et al.
lable at ScienceDirect
Atherosclerosis 237 (2014) 838e839Contents lists avaiAtherosclerosis
journal homepage: www.elsevier .com/locate/atherosclerosisInvited commentaryHigh-density lipoprotein and endothelial function in patients with
myocardial infarction: Pieces in a puzzle
Seth S. Martin*, Parag H. Joshi, Michael J. Blaha
Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USAa r t i c l e i n f oArticle history:
Received 8 October 2014
Accepted 19 October 2014





Myocardial infarctionLike the colorful lights of the aurora borealis, high-density li-
poproteins (HDLs) are full of character and inspire wonder. Their
extremely heterogeneous polymolecular complexity and multidi-
mensional functionality demands careful scrutiny, or else their
wondrous nuances could go unappreciated [1e3]. Indeed, while
epidemiological observations have suggested an important role of
HDL in protection from cardiovascular disease (CVD), recent clinical
trials have tempered enthusiasm over simply raising the quantity of
cholesterol within HDL [4e7]. The lack of positive clinical trials in
this space has only increased motivation for a deeper under-
standing of how pieces of the puzzle ﬁt together in the HDL-CVD
relationship.
Over the life course of an HDL particle, there is continual
remodeling of the lipidome and proteome, and these dynamic
structural changes appear to dictate functionality. Reverse choles-
terol transport is the classic function, but not necessarily the most
important one. Other described HDL functions include platelet
reactivity, heme metabolism, vitamin binding, insulin secretion,
immunity, and as addressed in this issue byCarvalho et al. [7]e anti-
oxidative/anti-inﬂammatory activity and regulation of endothelial
function.
Translational mechanistic studies like Carvalho et al.'s are
important to bridging the space between basic science andDOI of original article: http://dx.doi.org/10.1016/j.atherosclerosis.2014.10.103.
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Heart Study investigators examined 180 consecutive patients with
ST-elevation myocardial infarction (STEMI). Embracing the dy-
namic nature of HDL, assessments were performed at admission
and again at day 5 and day 30. The analysis showed that those with
higher admission HDL cholesterol levels (third tertile >42 mg/dL)
had a ~50% lower acute increase in plasma nitric oxide levels
compared to those with HDL cholesterol levels <33 mg/dL and
relatively less favorable endothelial function (~40% lower) at day 30
by ﬂow-mediated dilatation (FMD). The study team performed a
parallel anti-oxidative/anti-inﬂammatory protocol involving a
subset of 9 non-diabetic STEMI patients and 9 age- and sex-
matched healthy volunteers. Within 24 h of STEMI admission,
HDL showed similar capacity for preventing LDL oxidation relative
to healthy subjects, but STEMI patients then demonstrated signif-
icant impairment at day 5. It appeared that the acute inﬂammatory
response with STEMI brought dynamic structural changes in HDL
(reduction in apoA-I content) associated with impaired anti-
oxidant/anti-inﬂammatory activity, which may underlie the
observed relationship between HDL-C and FMD.
Guidelines view FMD as a research tool for non-invasive
assessment of vascular endothelial function [8]. After release of
arterial compression, blood ﬂow stimulates nitric oxide release in
healthy endothelium, inducing vasodilation that can be quantiﬁed
by ultrasound. Generally considered a technically-challenging
technique, FMD is best performed by experienced research teams
like the Brazilian Heart Study investigators. When measured in
expert laboratories, brachial artery FMD has been linked with
invasive coronary endothelial function testing and long-term car-
diovascular risk. However, standardizing FMDmeasurement across
individual patients and research labs poses a challenge given the
operator-dependency of the technique and possible variations in
measurement at different times of day or temperatures, for
instance. While FMD as a surrogate end-point is important and
interesting, hard outcome data are critical, a lesson that has been
learned the hard way in the HDL therapy world [2,6].
Regarding hard clinical outcomes, the authors noted the recent
report of a null predictive value for HDL-C in secondary prevention.
We [9] along with two other groups [10,11] have reached
compatible ﬁndings. In addition, it is worth noting that two Men-
delian randomization studies were not able to establish a causalr the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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come as a surprise tomany given thewidely ingrained beliefs about
HDL cholesterol's inverse relationship with risk.
Taking the line of investigation a step beyond total HDL
cholesterol, in secondary prevention patients, we examined the risk
associations of its two major subclasses: HDL2-C and HDL3-C [9].
Participants were from two modern, prospective, cohort studies:
Translational Research Investigating Underlying disparities in acute
Myocardial infarction Patient's Health status (TRIUMPH) registry
and Intermountain Heart Collaborative Study (IHCS). The comple-
mentary nature of the study populations enhances their general-
izability; TRIUMPH included STEMI and non-STEMI patients from
24 hospitals across the United States while the IHCS involved pa-
tients undergoing cardiac catheterization for a spectrum of coro-
nary indications. Although HDL2-C was not signiﬁcantly associated
with risk, those in the lowest tertile of HDL3-C had an approxi-
mately 50% higher risk of long-term mortality after accounting for
potential confounding variables. The smaller, denser, protein-rich
HDL3 subclass tends to carry about three-fourths of HDL choles-
terol [9] and most closely relates to the broad range of atheropro-
tective HDL functions [1]. As Carvalho et al. discuss, an acute
inﬂammatory surge related to myocardial infarction may induce
endothelial lipase and phospholipases, and attenuate lecithin-
cholesterol acyltransferase activity, in turn, resulting in denser,
cholesterol-depleted HDL particles. However, to what extent this
explains our results is unclear as blood specimens were drawn near
discharge in TRIUMPH and at the time of cardiac catheterization in
IHCS, and similar ﬁndings were reached.
Similar results were also reached in diverse primary prevention
populations inclusive of Caucasian and African-American men and
women from the Framingham Offspring Cohort and Jackson Heart
Studies, where evidence supports HDL3-C as the primary link to
coronary risk and mortality [14,15]. The longest available follow-up
(53 years) comes from Gofman's Livermore Cohort wherein ana-
lytic ultracentrifugationwas performed at baseline to measure HDL
subclass mass [15]. In an analysis of 1144 men, 34% survived to age
85, and the odds of survival were 70% higher for men above the
lowest quartile of HDL3-C compared to men within that lowest
HDL3-C group, a ﬁnding that persisted after adjustment for stan-
dard risk factors.
Given that low HDL3-C relates to risk similarly at different time
points in the context of secondary prevention, and also in primary
prevention, one cannot conclude that the acute HDL changes in the
context of myocardial infarction primarily explain the connection
between low HDL3-C and poor prognosis. Still, as the authors point
out, evidence indicates that HDL3 in myocardial infarction patients
is especially susceptible to oxidation. We can thus speculate that
one reason for the link of low HDL3-C to higher mortality risk may
be poor reserve in the oxidative buffering function of HDL and
greater vascular injury that may result. However, we suspect that
this would be one of multiple important mechanisms of injury and
risk.
Overall, we believe that there has been a long-standing chal-
lenge in the HDL ﬁeld to connect different lines of evidence. From
basic research to translational studies to population science to
clinical trials, we submit that there is a strong need to work
together to build the evidence in a collaborative and complemen-
tary fashion. Once pieces of the puzzle start ﬁtting together, then
we may start making sense of the mystery that is HDL. It is
important to consider how patient characteristics may impact re-
sults. The present study population was predominantly composed
of Brazilian men, with a large portion of smokers, whowere treated
with chemical revascularization. Whether the ﬁndings would have
been similar, for instance, in American women who are non-
smokers and treated with percutaneous coronary intervention isnot certain. Also, given statin therapy has an impact on both HDL-C
and inﬂammation, it will be important to carefully scrutinize the
relevance of this to the ﬁndings. Of course none of the healthy
volunteers in this study were taking statins.
In conclusion, Carvalho et al.'s documentation of dynamic
structural and functional changes in HDL during STEMI, and
connection of these changes with FMD, are an important addition
to the literature that further support the growing movement to-
wards a more sophisticated structural-functional characterization
of HDL. We look forward to following the Brazilian Heart Study and
learning how the ﬁndings in this study eventually map to hard
clinical outcomes. If our research community continues to be
inspired by the complexity of HDL and collaboratively embrace the
challenge of trying to understand it, we may ﬁt together the pieces
of the puzzle with this intricate lipoprotein and clarify whether it is
a viable therapeutic target in CVD.Support
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